AHCO: Q3 beat guidance as capitated-contract performance improved; FY26 revenue and EBITDA outlooks rose

What happened

Q3 revenue and adjusted EBITDA beat guidance as the largest capitated contract improved, while FY26 revenue and EBITDA outlooks rose. Free cash flow guidance was reduced, with debt reduction, cost discipline, and contract-margin recovery central to the outlook.

Confirmed

Global impact / market context

A capitated contract pays a fixed amount per patient, so better performance there can lift profit per sale and cash available. Higher revenue and EBITDA outlooks signal stronger operations, but lower free cash flow guidance means less cash after spending, which can slow debt reduction.

Analyst inference

Investors weighing AdaptHealth must balance improved contract performance and raised revenue and EBITDA outlooks against reduced free cash flow guidance. Less cash available after spending could limit debt reduction, so the mix of profit per sale recovery and cash generation will shape how the stock is valued.

Analyst inference

What to watch

1. Watch whether the largest capitated contract keeps improving, since that fixed per-patient payment structure was cited as the reason Q3 revenue and adjusted EBITDA beat guidance. Confirmed
2. Track whether cost discipline and contract-margin recovery, which the outlook calls central, are enough to offset the reduced free cash flow guidance and support debt reduction. Proposed
3. Watch free cash flow, which is cash left after spending, because weaker guidance there could slow debt reduction even as revenue and EBITDA outlooks rise. Analyst inference

Evidence

• Original source link unavailable